Probiotec Limited

PBP

AU000000PBP7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
2.83 ^AUD	-0.35%		-0.35%	-2.41%

Feb. 27	Probiotec Limited Declares Interim Dividend, Payable on 15 March 2024	CI
Feb. 27	Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2023

February 27, 2024 at 04:59 pm EST

Probiotec Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported sales was AUD 113.96 million compared to AUD 106.77 million a year ago. Net income was AUD 3.13 million compared to AUD 5.46 million a year ago.

Basic earnings per share from continuing operations was AUD 0.0385 compared to AUD 0.0671 a year ago. Diluted earnings per share from continuing operations was AUD 0.0373 compared to AUD 0.0662 a year ago.

Latest news about Probiotec Limited

Probiotec Limited Declares Interim Dividend, Payable on 15 March 2024	Feb. 27	CI
Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Probiotec Enters Scheme Implementation Bid With Indonesia-Listed Pyridam Farma	Dec. 25	MT
Probiotec Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-24	CI
Probiotec Limited Declares Fully Franked Final Dividend for the Period of Six Months Ended June 30, 2023 , Payable on 8 September 2023	23-08-24	CI
Probiotec Limited Provides Sales Guidance for the Fiscal 2023	23-02-23	CI
Probiotec Limited Declares an Interim Dividend Payable on 17 March 2023	23-02-23	CI
Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Probiotec to Consolidate NSW Operations with New Large-Scale Facility in Sydney	22-11-28	MT
Probiotec Limited Enters Agrees Terms with Major Australian Developer for Circa 30,000 Sqm Facility in Kemps Creek, NSW	22-11-27	CI
Probiotec Limited Announces Resignation of Paul Santoro as Non-Executive Director	22-10-17	CI
Probiotec Limited(ASX:PBP) dropped from S&P/ASX Emerging Companies Index	22-09-19	CI
Probiotec Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-23	CI
Probiotec Limited Announces Ordinary Fully Paid Dividend for the Twelve Months Ended June 30, 2022, Payable on September 15, 2022	22-08-23	CI
Probiotec Limited Provides Earnings Guidance for the Full Year 2022	22-02-24	CI
Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-24	CI
Probiotec Limited Announces Distribution for the Six Months Ended December 31, 2021, Payable on March 18, 2022	22-02-24	CI
Probiotec Limited Appoints Paul Santoro as Non-Executive Director	22-01-27	CI
Probiotec Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-24	CI
Probiotec Limited Declares Final Dividend for the Financial Year Ended 30 June 2021, Payable on 8 October 2021	21-08-24	CI
Probiotec : Acquires H&H Packaging for Up to $2.9 Million	21-08-02	MT
Probiotec Limited (ASX: PBP) completed the acquisition of assets and business of H&H Packaging.	21-07-31	CI
Probiotec : To Acquire H&H Packaging for up to $3 Million; Shares Up 5%	21-06-28	MT
Probiotec Limited Appoints Simon Gray as an Independent Non-Executive Director, Effective 1 July 2021	21-06-27	CI
Probiotec Limited entered in an agreement to acquire assets and business of H&H Packaging Pty Ltd for AUD 4 million.	21-06-27	CI

Chart Probiotec Limited

Duration

Period

More charts

Company Profile

Probiotec Limited is an Australia-based manufacturer, packer and distributor of a range of prescription and over the counter (OTC) pharmaceuticals, complementary medicines, consumer health products, and fast-moving consumer goods (FMCG). The Company owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. It offers full-service contract manufacturing and packing. The Company manufactures products on behalf of a range of clients, including international pharmaceutical companies. The Company services blue-chip manufacturers, multinational FMCG companies, local manufacturers and brand custodians. All types of FMCG products are packed or handled, such as canned food, alcohol, tea and coffee, dairy and frozen foods, sauces and condiments, and bottled water. Its subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Multipack-LJM Pty Ltd, LJM (NSW) Pty Ltd and HH Packaging Pty Ltd.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Probiotec Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.83 AUD

Average target price

3 AUD

Spread / Average Target

+6.01%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROBIOTEC LIMITED	-2.41%	150M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals